HYUNDAI BIOSCIENCE CO. LTD. 048410
KRX · South Korea · Health Technology
KRW 7,220.00+170.00 (+2.41%)
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Hyundai Bioscience USA announced on June 10 that it has pledged to provide its broad-spectrum antiviral candidate, XAFTY® (CP-COV03), free of charge for emergency use and/or testing for patients in African countries experiencing Ebola outbreaks.
Hyundai Bioscience announced on May 20th that XAFTY® has a strong likelihood of being able to treat Ebola and Hantavirus given its low IC50 (50% inhibitory concentration) for those viruses. Amid the current crisis of these two often fatal infectious diseases XAFTY® should be considered for testing.
Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.